Kenneth S. Abramowitz

Kenneth S. Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine "All-America Research Team" during 14 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987. Mr. Abramowitz has published several notable studies on healthcare service companies, major medical mergers, and cardiovascular device innovation, among others. He has also published numerous articles in leading journals. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the Board of Directors of EKOS Corporation, OptiScan Biomedical Corporation, MultiPlan Acquisition Holdings, Cerapedics, Inc., Valtech Cardio and Small Bone Innovations, Inc. He previously served as a Director at Sightline Technologies Ltd and Power Medical Interventions, as well as MedPointe and ConnectiCare Holdings, Inc.

.John R. Costantino

John R. Costantino is a Managing General Partner at NGN Capital with 20 years of private equity experience. He was formerly a Partner of Walden Partners, a merchant/investment banking firm and Walden Capital Partners. Prior to these assignments, Mr. Costantino was a partner in Costantino, Melamede & Greenberg, an investment partnership which specialized in acquiring and managing growth businesses. He was also Senior Executive Vice President & COO and a Director of Conair, a leading personal care company with over $1 billion of revenues. He was also President and a Managing Director of Integrated Resources Acquisition, a leveraged buyout firm. He started his career at Touche Ross, a major accounting firm where he became the firm’s managing tax partner in New York. Mr. Costantino is a trustee of General Electric’s family of mutual funds. He holds a B.S. and J.D. from Fordham University and is also a C.P.A. Mr. Costantino is Chairman of Enzybiotics, Inc. and Senior Advisor to Promosome LLC, two biotechnology start-ups formed prior to NGN Capital. He also serves on the Board of Directors of ACT Biotech, a spin-out from Bayer Pharmaceuticals, Artisan Pharma, Inc. and Medrium Corporation. He continues to participate and has served on a number of other domestic and international boards.

Peter Johann, Ph.D.

Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine. Besides marketing activities Dr. Johann was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities in this field. Prior to that position he had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals. Dr. Johann has additional industry experience in Business Development and Marketing of pharmaceutical products with Kaneka in Japan and with Röhm in Germany in industrial enzymes. Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of Micromet, Inc. (Nasdaq: MITI), Nitec Pharma AG, NaniRx Therapeutics, Vivaldi Biosciences and Resverlogix Corporation and as a board observer at Cerapedics. He previously served on the Board of Directors of Jerini AG (FWB: J14) and as an observer on the board of Santhera Pharmaceuticals AG.

Georg Nebgen, Ph.D.

Dr. Georg Nebgen is a co-founder and Managing General Partner of NGN Capital. He joined from MPM Capital where he had previously been a Principal at MPM Capital in Boston and Managing Director of MPM Capital GmbH. Prior to this, Dr. Nebgen was with Schering-Plough Corporation, as Managed Care Area Manager for New England. His responsibilities included contracting the reimbursement of Schering-Plough’s ethical pharmaceutical products and services with managed care organizations, as well as leading sales pull-through activities of the field forces. Prior to this, Dr. Nebgen had served in Schering-Plough's subsidiary in Switzerland as Business Unit Head, Oncology & Biotech and Business Unit Head, Cardiovascular & CNS. Dr. Nebgen joined Schering-Plough from F. Hoffmann-La Roche, where he led as Technical Project Leader the global research & development team for Invirase/Fortovase its NDA filing, FDA approval, and subsequent product launch in the United States. He obtained his doctorate in Pharmaceutical Technology Sciences from the University of Bonn, Germany and his executive MBA from the University of St. Gallen, Switzerland. He is the recipient of awards in both science and business. He served as the President of the German-American Business Council in Boston. Dr. Nebgen currently serves on the Board of Directors of Javelin Pharmaceuticals, Inc. (AMEX: JAV), , Artisan Pharma, Inc., KIKA Medical Inc., and Tigris Pharmaceuticals, Inc. He also serves as a Director for ACT Biotech, Valtech Cardio and Vivaldi Biosciences. He previously served as a Director of Kourion, acquired by Viacell (Nasdaq: VIAC),Omrix (Nasdaq: OMRI), and Santhera Pharmaceuticals AG (SWX: SANN)

Bernard Peperstraete, M.D.

Dr. Bernard Peperstraete is a Principal of NGN Capital. Prior to NGN, Dr. Peperstraete served as a Principal at Masa Life Science Ventures, where he focused on early stage life science opportunities. His previous life science operating roles include hospital manager, medical entrepreneur, sales and marketing executive and physician. In 2004, Bernard worked at Novartis where he evaluated the commercial market potential for emerging indications. Before completing his MBA at Harvard, Dr. Peperstraete was a Deputy Director at the Tan Tock Seng Hospital (TTSH-CDC) in Singapore and was responsible for medical manpower coordination during the SARS crisis. Prior to CDC, he successfully co-founded and ran an Infectious Disease contract research business, also in Singapore. In 1999, after serving as a physician, Dr. Peperstraete managed the HIV business unit at Bristol Myers & Squibb, Singapore. Bernard is a Kauffman Fellow and was nominated a Fulbright scholar and a Belgian American Education Foundation (BAEF) fellow at Harvard. He earned his MD at the Katholieke Universiteit Leuven in Belgium and his specialist diploma in Tropical Medicine, also in Belgium. He currently holds observer seats on the boards of ACT Biotech and Exosome Diagnostics. At NGN, Bernard is further involved with the Noxxon AG and the Artisan Pharmaceuticals transactions. He previously served as a Director at Potentia Pharmaceuticals (Alcon).

Leonard Hirsch

Leonard P. Hirsch, CPA, is the Chief Financial Officer of NGN Capital. Mr. Hirsch comes to NGN Capital with over 15 years of experience in tax, accounting and financial administration. Most recently he was the Chief Financial Officer of Wheatley Partners, a venture capital group with $300 million under management, focused on software and technology related investments. In this role he was responsible for financial and tax reporting, limited partner communications, and fund administration. Prior to this position, he worked with a technology start-up as it grew from about twenty to over 100 employees upon the completion of venture capital financing. Mr. Hirsch’s responsibilities included financial reporting, tax compliance, budgeting, development of accounting policies, and general administrative matters. Mr. Hirsch began his career with PricewaterhouseCoopers, spending seven years in the New York office and specializing in corporate and partnership taxation. His clients ranged from start-ups to multinational corporations in the consumer, media, retail and financial service sectors. Mr. Hirsch received a B.S in business administration from the University of Vermont and a Masters in Accounting and Taxation from Fordham University.

Kenneth J. Gorelick, M.D.

Kenneth Gorelick, M.D. has 20 years of experience in the development of drugs and biologics in the human health care sector. He is currently President and Chief Operating Officer of Enzybiotics, LLC, a privately held biotechnology company and a consultant to the pharmaceutical industry. Dr. Gorelick has expertise with numerous approvals of BLAs, NDAs and MAAs. Prior to these assignments, Dr. Gorelick held the position of Vice President of Global Clinical Research and Development at Dupont Merck Research Laboratories, Inc. a research-driven pharmaceutical company. He was also Vice President of Drug Development at Genelabs, a biotechnology company focused on infectious and autoimmune disease. Dr. Gorelick was Clinical Associate Professor of Medicine at Stanford University until 2000. He holds a B.S. from the State University of New York at Buffalo and a M.D. from Weill Medical College of Cornell University. He is Board Certified in Internal Medicine and Pulmonary Diseases. He is a Fellow of the American College of Chest Physicians.

Leon Y. Recanati

Leon Y. Recanati is currently the Chairman and CEO of GlenRock Israel Ltd., a private investment company whose main field of activity is venture capital investments in startup companies engaged in life sciences, biotechnology, medical devices, and in advanced technologies. Until May 2003, and prior to founding GlenRock, he served as Chairman & CEO of IDB Holding Corporation Ltd., Chairman of Clal Industries and Investments Ltd., and Chairman of Azorim Investment Development and Construction Ltd., in addition to several other positions in a variety of operating companies in Israel. Mr. Recanati initiated in 1998 Clal Biotechnologies Ltd. (CBL). Clal Industries invested $100 million in CBL. Clal Biotechnologies is considered the largest biotechnology investment company operating in Israel. Mr. Recanati has a M.B.A. and B.S. from The Hebrew University of Jerusalem and Honorary Doctorate degrees from the Technion - Israel Institute of Technology and Tel Aviv University. Mr. Recanati is actively heading numerous charitable enterprises in Israel..

Colin B. Bier, PhD

Colin B. Bier, PhD is currently the Managing Director of ABA BioResearch, Inc., a bioregulatory consulting firm. He is also currently the Acting Chief Scientific Officer of Enzybiotics, Inc. and a Senior Advisor to TVM Venture Capital. Dr. Bier has had experience in operating, medical, scientific and strategic advisory roles at a variety of pharma/biopharma companies. At present, he is a member of the Boards of Directors of two public companies, Bellus Health and Advitech, Inc., as well as serving on other private company boards. He is on the Board of Directors of Mt. Sinai Hospital (Montreal) and holds an appointment at The Center for Translational Research in cancer at the Jewish General Hospital (Montreal). Dr. Bier earned a Ph.D. in Experimental Pathology at Colorado State University and was the former Medical Research Council Postdoctoral Fellow and The Dr. Douglas James Fellow in the Department of Pathology at McGill University.

William J. Gedale

William J. Gedale is a Senior Advisor and co-founder of NGN Capital. He has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. He has served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm, between 1999 and 2001. In this capacity, he initiated the $140 million dollar financing of ZymoGenetics. He also helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Institute of La Jolla, California (of which he is a trustee). Before founding Mount Everest Advisors he was a Managing Director at John W. Bristol & Co. in 1995. Before this, as of 1989, Mr. Gedale was President & Chief Executive Officer of General American Investors, which he had joined in 1969. He is currently Chairman of Promosone and Vice Chairman of Enzybiotics. He has been a director of Gamco (Gabelli Holding), General American Investors, Allied Clinical Laboratories, U.S. Home Health Care, Unilab Corporation, and BioReliance Corporation. William Gedale holds an M.B.A. from New York University, a J.D. from Fordham Law School, and an A.B. from Syracuse University. He currently serves on the Board of Directors of KIKA Medical Inc.